Edition:
United Kingdom

WAVE Life Sciences Ltd (WVE.OQ)

WVE.OQ on NASDAQ Stock Exchange Global Market

37.10USD
8:59pm GMT
Change (% chg)

$0.55 (+1.50%)
Prev Close
$36.55
Open
$36.70
Day's High
$37.50
Day's Low
$36.35
Volume
41,828
Avg. Vol
45,240
52-wk High
$39.70
52-wk Low
$15.15

Chart for

About

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects... (more)

Overall

Beta: --
Market Cap(Mil.): $694.01
Shares Outstanding(Mil.): 27.76
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Wave Life Sciences Reports Data From Preclinical Studies Testing WVE-3972-01

* WAVE LIFE SCIENCES - ANNOUNCED DATA FROM PRECLINICAL STUDIES OF WVE-3972-01 FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA

11 Dec 2017

BRIEF-Wave Life Sciences Q3 net loss of $26.1 million

* Wave Life Sciences reports third quarter 2017 financial results and provides business update

09 Nov 2017

BRIEF-Wave Life Sciences opens new 90,000 square foot manufacturing facility

* Wave Life Sciences Ltd - ‍public opening of its new 90,000 square foot manufacturing facility and office space in Lexington, Massachusetts​ Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-Teva pharmaceutical reports 5 pct stake in Wave Life Sciences as of Aug 30, 2017 versus 9 percent stake as of Nov 16, 2015

* Teva Pharmaceutical Industries Limited reports 5 percent stake in Wave Life Sciences Ltd as of Aug 30, 2017 versus 9 percent stake as of Nov 16, 2015 - SEC filing‍​ Source text: (http://bit.ly/2w4qQej) Further company coverage:

05 Sep 2017

BRIEF-Wave Life Sciences qtrly loss per share $0.92‍​

* Wave life sciences reports second quarter 2017 financial results and provides business update

09 Aug 2017

BRIEF-Wave Life Sciences initiates two Phase 1b/2a clinical trials PRECISION-HD1 and PRECISION-HD2 in patients with Huntington’S Disease

* Wave Life Sciences Ltd - ‍trials evaluate first allele-specific investigational drugs for Huntington's Disease, WVE-120101 and WVE-120102​ Source text for Eikon: Further company coverage:

17 Jul 2017

Earnings vs. Estimates